# Eli Lilly and Company – Consensus ‘buy’ rating and 1.9% Upside Potential

- Link: https://www.directorstalkinterviews.com/eli-lilly-and-company-consensus-buy-rating-and-1.9-upside-potential/4121131005
- Published: 2023-10-26T12:44:29+01:00
- Author: Charlotte Edwards

**Eli Lilly and Company** which can be found using ticker (LLY) have now 24 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
target price High/Low ranges between 710 and 340 and has a mean target at $603.57.
Now with the previous closing price of $592.43 this now indicates there is a potential
upside of 1.9%. The 50 day MA is $567.72 and the 200 day MA is $440.08. The company
has a market cap of 556.72B. The stock price is currently at: 586.46 USD

 The potential market cap would be $567,192,114,758 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 82.02, revenue per share of 32.76
and a 10.18% return on assets.

Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers,
develops, manufactures, and markets products in the human pharmaceutical products
segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro,
and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Jaypirca,
Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant and Taltz.
Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies
consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains
special business groups for service wholesalers, pharmacy benefit managers, managed
care organizations, group purchasing organizations, government and long-term care
institutions, hospitals, and certain retail pharmacies. It manufactures and distributes
its products through facilities in the United States, including Puerto Rico, and
other countries. Its products are sold in over 110 countries.

Share on: